GlassScriptPhysician profile
Lisa Arsenault
NPI 1841427804
$751.79
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $113 · 2022: $248 · 2023: $364 · 2024: $25.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $299 · Food and Beverage: $90.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $299.10 |
| Food and Beverage | $90.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $407.12 | 2022-2023 | |
| Incyte Corporation | $98.95 | 2022 | |
| Janssen Biotech, INC. | $29.56 | 2022 | |
| Puma Biotechnology, INC. | $27.73 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $26.15 | 2021 | |
| Abbvie INC. | $25.60 | 2024 | |
| Daiichi Sankyo INC. | $25.47 | 2023 | Injectafer |
| Karyopharm Therapeutics INC. | $23.40 | 2021 | |
| Lilly USA, LLC | $21.05 | 2021 | |
| Glaxosmithkline, LLC. | $20.27 | 2022 | |
| Merck Sharp & Dohme LLC | $18.50 | 2023 | Keytruda |
| Pharmacyclics LLC, An Abbvie Company | $14.92 | 2021 | |
| Amgen INC. | $13.07 | 2023 | Lumakras |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Arsenault listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.